Latest News and Press Releases
Want to stay updated on the latest news?
-
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
-
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results
-
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data from the study expected in the third quarter of 2025...
-
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors
-
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
-
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
-
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
-
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
-
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
-
aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations